Baculovirus-expressed influenza vaccine: A novel technology for safe and expeditious vaccine production for human use

Expert Opinion on Investigational Drugs

Volumn 16, Issue 7, 2007, Pages 927-934

  Safdar, Amar ^a   Cox, Manon M J ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Protein Sciences Corp   (United States)

Author keywords

Baculovirus recombinant vaccine; Immunogenicity; Influenza vaccine; Lyphoma; Vaccine development

Indexed keywords

ANTINEOPLASTIC AGENT; HEMAGGLUTINATION INHIBITING ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; MUSCARINIC M2 RECEPTOR AGONIST; RECOMBINANT ANTIGEN; RECOMBINANT DNA; RECOMBINANT VACCINE; SIALIDASE; VIRUS VACCINE;

ANTIBODY RESPONSE; BACULOVIRUS EXPRESSION SYSTEM; CELL BASED GENE THERAPY; CLINICAL TRIAL; DNA VECTOR; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOGENICITY; INFLUENZA; INSECT CELL; LYMPHOMA; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION;

ANIMALS; BACULOVIRIDAE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUGS, INVESTIGATIONAL; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEURAMINIDASE; ORTHOMYXOVIRIDAE; SENSITIVITY AND SPECIFICITY; VACCINES, INACTIVATED;

EID: 34447500383     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.7.927     Document Type: Review

References (48)

1. COUCH RB: Prevention and treatment of influenza. N. Engl. J. Med. (2000) 343:1778-1787.
2. SAFDAR A, ARMSTRONG D: Infectious morbidity in critically ill patients with cancer. Crit. Care Clin. (2001) 17:531-570.
3. COUCH RB: Influenza, influenza virus vaccine, and human immunodeficiency virus infection. Clin. Infect. Dis. (1999) 28:548-551.
4. ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES; SMITH NM, BRESEE JS, SHAY DK, UYEKI TM, COX NJ, STRIKAS RA: Prevention and control of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Recomm. Rep. (2006) 55:1-42.
5. MUNOZ FM, GALASSO GJ, GWALTNEY JM et al.: Current research on influenza and other respiratory viruses: II International Symposium. Antiviral Res. (2000) 46:91-124.
6. + lymphocytes. AIDS (1994) 8:469-476.
7. GANDHI MK, EGNER W, SIZER L et al.: Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Trasplant. (2001) 28:775-781.
8. ROBERTSON JD, NAGESH K, JOWITT SN et al.: Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenza type B in patients with multiple myeloma. Br. J. Cancer (2000) 82:1261-1265.
9. HERRERA GA, IWANE MK, CORTESE M et al.: Influenza vaccine effectiveness among 50 - 64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, US, 2003 - 2004. Vaccine (2007) 25(1):154-160.
10. LO W, WHIMBEY E, ELTING L, COUH R, CABANILLAS F, BODEY G: Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur J. Clin. Microbiol. Infect. Dis. (1993) 12:778-782.
11. LJUNGMAN P, NAHI H, LINDE A: Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br. J. Haemtol. (2005) 130:96-98.
12. RAPEZZI D, STICCHI L, RACCHI O, MANGERINI R, FERRARIS AM, GAETANI GF: Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma. Eur. J. Haematol. (2003) 70:225-230.
13. MOSTOW SR, DOWDLE WR, SCHOENBAUM SC, COLEMAN MT, KAYE HS: Inactivated vaccines. I. Volunteer studies with very high doses of influenza vaccine purifies by zonal ultracentrifugation. Postgrad. Med. J. (1973) 49:152-158.
14. PARKMAN PD, HOPPS HE, RASTOGI SC, MEYER HM Jr. Summary of clinical trials of influenza virus vaccines in adults. J. Infect. Dis. (1977) 136:S722-S730.
15. LAKEY DL, TREANOR JJ, BETTS RF et al.: Recombinant Baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J. Infect. Dis. (1996) 174:838-841.
16. TREANOR JJ, SCHIFF GM, COUCH RB et al.: Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J. Infect. Dis. (2006) 193:1223-1228.
17. KEITEL WA, ATMAR RL, CATE TR et al.: Safety of high dose of influenza vaccine and effect on antibody responses in elderly persons. Arch. Intern. Med (2006) 166:1121-1127.
18. SAFDAR A, RODRIGUEZ MA, FAYAD LE et al.: Dosc-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin's lymphoma. J. Infect Dis. (2006) 194:1394-1397.
19. COX MMJ, ANDERSON KD: Production of novel influenza vaccine using insect cells: protection against drifted strains. Influenza and Other Respiratory Viruses (2007) 1:35-40.
20. HOLTZ, KM, ANDERSON DK, COX MMJ: Production of a recombinant influenza vaccine using the baculovirus expression vector system. Bioprocess J. (2003) 2(5):65-73.
21. WANG K, HOLTZ KM, ANDERSON K, CHUBET R, MAHMOUD W, COX MM: Expression and purification of an influenza hemagglutinin - one step closer to a recombinant protein-based influenza vaccine. Vaccine (2006) 24:2176-2185.
22. LAMB RA. Genes and proteins of the influenza viruses. In: The Influeza Viruses. Krug RM (Ed.), Plenum Press, New York, USA (1989):1-87.
23. KILBOURNE ED, CERINI CP, KHAN MW, MITCHELL JW Jr, OGRA PL: Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated vital hemagglutinin. I. Studies in human vaccinees. J. Immunol. (1987) 138:3010-3013.
24. MURPHY BR, KASEL JA, CHANOCK RM: Association of serum and-neuraminidase antibody with resistance to influenza in man. N. Engl. J. Med. (1972) 286:1329-1332.
25. DEROO T, JOU WM, FIERS W: Recombinant neuraminidase vaccine protects against lethal influenz. Vaccine (1996) 14:561-569.
26. JOHANSSON BE, PRICE PM, KILBOURNE ED: Immunogenicity of influenza virus N2 neuraminidase produced in insect larvae by baculovirus recombinants. Vaccine (1995) 13:841-845.
27. KILBOURNE ED, POKORNY BA, JOHANSSON B, BRETT I, MILEV Y, MATTHEWS JT. Protection of mice with recombinant influenza virus neuraminidase. J. Infect. Dis. (2004) 189:459-461.
28. MATTHEWS J: Preclinical and clinical evaluation of a purified, baculovirus-expressed influenza neuraminidase antigen. The Baculovirus & Insect Cell Culture Conference. San Antonio, USA (21 - 24 February 2000).
29. PINTO LH, HOLSINGER LJ, LAMB RA: Influenza virus M2 protein has ion channel activity. Cell (1992) 69:517-528.
30. SUGRUE RJ, HAY AJ: Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology (1991) 180:617-624.
31. ITO T, GORMAN OT, KAWAOKA Y, BEAN WJ, WEBSTER RG: Evolutionary analysis of the influenza A virus M gene with comparison of die M1 and M2 proteins. J. Virol. (1991) 65:5491-5498.
32. ZEBEDEE SL, LAMB RA; Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol. (1988) 62:2762-2772.
33. TREANOR JJ, TIERNEY EL, ZEBEDEE SL, LMB RA, MURPHY BR: Passively transferred monoclonal antibodies to the M2 protein inhibits influenza A virus replication in mice. J. Virol. (1990) 64:1375-1377.
34. SLEPUSHKIN VA, KATZ JM, BLACK RA, GAMBLE WC, ROTA PA, COX NJ: Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine (1995) 13:1399-1402.
35. BLACK RA, ROTA PA, GORODKOVA N, KLENK HD, KENDAL AP: Antibody responses of the M2 protein of influenza A virus expressed in insect cells. J. Gen. Virol. (1993) 74:143-146.
36. + channel: the gating mechattism of influenza A M2. Structure (2005) 13:1789-1798.
37. PINTO LH, LAMB RA. The M2 proton channels of influenza A and B viruses. J. Biol. Chem. (2006) 281:8997-9000.
38. HAY AJ, WOLSTENHOLME AJ, SKEHEL JJ, SMITH MH: The molecular basis of the specific anti-influenza action of amantadine. EMBO J. (1985) 4:3021-3024.
39. LAMB RA, KRUG RM: Orthomyxoviridae: the viruses and their replication. In: Fields Virology. Knipe DM, Howley PM (Eds), Lippincott Williams & Wilkins, Philadelphia, USA (2001) 4:1487-1531.
40. FRACE AM, KLIMOV AI, ROWE T, BLACK RA, KATZ JM: Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine (1999) 17:2237-2244.
41. NEIRYNCK S, DEROO T, SAELENS X, VANLANDSCHOOT P, JOU WM, FIERS W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. (1999) 5:1157-1163.
42. FAN J, LIANG X, HORTON MS et al.: Predinical study of influenza virus A M2 peptide conjugate vaccine in mice, ferrets, and rhesus monkeys. Vaccine (2004) 22:2993-3003.
43. HEINEN PP, RIJSEWIJK FA, DE BOER-LUIJTZE EA, BIANCHI ATJ: Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J. Gen. Visrol. (2002) 83:1851-1859.
44. HIEN TT, DE JONG M, FARRAR J: Avian influenza - a challenge to global health care structure. N. Engl. J. Med. (2004) 351:2363-2365.
45. STEPHENSON I, NICHOLSON KG, WOOD JM, ZAMBON MC, KATZ JM: Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet (2004) 4:499-509.
46. TREANOR JJ, CAMPBELL JD, ZANGWILL KM, ROWE T, WOLFF M: Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. (2006) 354:1343-1351.
47. CRAWFORD J, WILKINSON BE, VOSNESENSKY A et al.: Baculovirus-derived rHA vaccines protect against lethal influenza infections by avian H5 & H7 subtypes. Vaccine (1999) 17:2265-2274.
48. TREANOR JJ, WILKINSON BE, MASSEOUD F et al.: Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans vaccine. Vaccine (2001) 19:1732-1737.